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Introduction 
Inherited arrhythmia syndromes encompass a number of different diseases including long QT 
syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular 
tachycardia (CPVT), short QT syndrome (SQTS), idiopathic ventricular fibrillation (IVF) and 
progressive cardiac conduction system disease (PCCD).1 The heart is typically structurally 
normal with no evidence of disease macroscopically. They are an important cause for sudden 
cardiac death (SCD) in the young and an autopsy is typically negative.2, 3 
Ventricular arrhythmias are due to mutations of ion channels and their interacting 
proteins, predominantly involving potassium, sodium and calcium handling.4 Genetic studies 
have identified the specific genetic abnormalities that underpin these diseases even permitting 
diagnosis in the deceased using post-mortem genetic testing (the “molecular autopsy”).3 Most 
arrhythmia syndromes are inherited in an autosomal dominant manner, such that first degree 
family members have a 50% chance of inheriting the disease. Identification of the mutation 
allows for predictive genetic testing in other living family members.4 ‘Variable penetrance’ is 
common in all arrhythmia syndromes, the same mutation in the same family causing wide 
variation in phenotype.4 This suggests that other factors such as genetic modifiers and 
environmental factors may influence the phenotype. 
This review will highlight the latest developments in understanding the genetic basis of 
inherited arrhythmia syndromes and discusses the new opportunities and challenges faced with 
evolving genetic technologies including determining pathogenicity and the utility of large 
genetic databases. Finally, we will discuss newly described entities that continue the evolving 
theme of genetic syndromes with phenotypic overlap. Early views that a single genotype 
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associates with a particular phenotype continue to be challenged by our greater understanding of 
the genotype phenotype relationship. 
Inherited Arrhythmia Syndromes 
Long QT Syndrome 
Congenital LQTS is diagnosed in the presence of a prolonged corrected QT (QTc) interval after 
secondary causes (e.g. QT-prolonging medications or electrolyte abnormalities) are excluded.1 
The 2013 HRS/EHRA/APHRS guidelines recommended that LQTS also be diagnosed in the 
presence of an LQTS risk (Schwartz) score ≥3.5 or in the presence of an unequivocally 
pathogenic variant in one of the known LQTS genes.1 Patients with un xplained syncope and a 
borderline QTc between 480-499ms in recurrent ECGs, or who were asymptomatic but had 
repeated measurements of over 500ms, may also be diagnosed with LQTS.1 The more recent 
2015 ESC guidelines softened these criteria to QTc≥480ms in an asymptomatic patient or a QTc 
≥460ms in the presence of unexplained syncope.5 It was argued that higher values equated to 
high risk LQTS and were therefore too conservative.  
QT prolongation results from ion channel dysfunction that prolongs cellular 
repolarisation.6, 7 There are currently 15 genes known to cause congenital LQTS, however the 
main 3 genotypes account for >90% of genetically confirmed LQTS (Table 1).1, 4 The genetic 
cause remains elusive in 25% of LQTS families.12 LQT1 is caused by loss of function mutations 
affecting KCNQ1 the gene encoding for IKs (slow) channel.4 Both haploinsufficiency and 
dominant-negative mechanisms of KCNQ1 mutations are described.13, 14 LQT2 is caused by loss 
of function mutations in KCNH2 the gene encoding for the IKr (rapid) channel predominantly due 
to failure of trafficking to the cell membrane surface.15, 16 Gain of function mutations in SCN5A, 
the gene encoding for INa, causes failed inactivation and increased late current leading to LQT3.17 
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Whilst most LQTS is inherited in an autosomal dominant manner, the rare recessive form 
(Jervell and Lange-Nielsen Syndrome [JLNS]) leads to a severe LQTS phenotype and associated 
sensorineural deafness.18 Indeed, greater severity is typical when more than one mutation is 
identified.4  
A recent study has suggested that LQTS may be preferentially transmitted from the 
maternal allele, with higher than expected maternal transmission and inheritance, particularly 
with LQT1.19 The authors also found that this phenomenon was not linked to locus-specific 
grandparental origin allele transmission distortion and in fact appears to be related to the severity 
of channel dysfunction. The authors postulate that that altered potassium channel function may 
modulate reproduction, particularly KCNQ1 which is expressed in the granulosa and 
trophoblastic cells of the ovaries.19 LQTS-associated potassium channel dysfunction has also 
been proposed recently as a possible mechanism for some stillbirths given that LQTS 
susceptibility variants can be identified in some cases.20 This hypothesis follows on from 
evidence that some sudden infant death syndrome (SIDS) may also be due to LQTS.4  
Common variants (single nucleotide polymorphism or SNPs) at the NOS1AP locus have 
been shown to modify phenotype by affecting both the QT interval and the likelihood of 
symptoms in LQTS, whilst common variants in KCNQ1 within the 3’untranslated region may 
also influence disease severity.21-23 A recent genome-wide association and replication study 
identified a total of 35 SNP tagged loci associated with QT interval amongst around 100,000 
individuals of European ancestry, 6 of which were found to have rare coding variants in LQTS 
patients absent in controls.24 Whilst this does not equate to pathogenicity, it is likely that these 
loci may also modify the LQTS phenotype to some extent.  
Genotyping in LQTS is useful diagnostically, therapeutically and to a lesser extent,  
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prognostically.1, 12 Beta-blockers are the mainstay of therapy, with LQT1 patients, particularly 
those with mutations in cytoplasmic loops, most protected regardless of drug and LQT2 patients 
responding best to nadolol.25, 26 Sodium channel blockers (e.g. mexiletine) can be useful in 
addition to betablockers for patients who have LQT3.27 High risk features include severe QT 
prolongation, boys, female adults, prior cardiac arrest and syncope despite beta-blocker therapy. 
However only LQT2 females and those with high risk genetic profiles (i.e. multiple mutations or 
JLNS) have been associated with sufficient additional risk to suggest a potential risk-stratifying 
role.5  Additionally the biophysical consequences of the mutation may offer alternative methods 
for stratification.28   
Brugada Syndrome 
BrS was first formally described in 1992, whereby Brugada et al reported 8 patients with 
characteristic cove-shaped ST elevation in the right precordial leads with associated SCD due to 
ventricular fibrillation (VF).29 Diagnostic criteria from a recent consensus report require the 
patient to have a spontaneous type 1 Brugada pattern ECG defined as ≥2mm ST elevation with 
type 1 morphology in ≥1 right precordial lead V1 or V2 in either 2nd, 3rd or 4th intercostal 
space.30 Unlike the earlier 2013 Guidelines,1  if the type 1 pattern is only revealed after sodium 
channel blocker challenge, the diagnosis of BrS also requires one of the following: documented 
VF or polymorphic ventricular tachycardia (VT), suspected arrhythmic syncope, family history 
of SC  with negative autopsy, BrS ECG in family members, or nocturnal agonal respiration. 
This follows recent data suggesting a higher than expected yield of positive results in ajmaline 
provocation tests in an apparently healthy control population.31  
Traditionally BrS has been proposed as a primary electrical disease  involving a relative 
impairment of the inward sodium current compared to the transient outward potassium current 
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(Ito) in the right ventricular outflow tract (RVOT).30 However a transgenic mini-pig model of a 
truncating SCN5A mutation showed evidence of conduction disease but without a type 1 ECG 
pattern.32 This may reflect that haploinsufficiency leads to an isolated conduction disease 
phenotype without the necessary further genetic variation associated with BrS in humans (see 
below); the young age of the pigs given that BrS exhibits age related penetrance; and/or the 
absence of Ito in the pig myocardium. The diagnosis of BrS has also required the exclusion of 
overt structural heart disease and the pathophysiology has been attributed to transmural and 
epicardial heterogeneity of repolarization. However, there is mounting evidence that BrS may 
represent one end of a spectrum of subtle structural disease.33 In particular imaging studies have 
suggested abnormalities of the right ventricle and RVOT.34, 35 Epicardial ablation studies have 
identified fractionated signals consistent with slowed conduction and fibrosis which have been 
confirmed by other investigators both invasively and using ECG imaging.36-38 Subsequent 
pathological studies in open surgical ablation and sudden death victims from BrS families have 
confirmed subtle epicardial fibrosis and reduced connexin-43 in the RVOT.39 An experimental 
perfused canine wedge model has however proposed that these fractionated potentials may result 
from phase II re-entry.40 
BrS has traditionally been considered as an autosomal dominant inherited disease. 
However, this convention has also been challenged. The most common associated genetic 
abnormality is a loss of function mutation in SCN5A. However, a mutation is identified in only 
one fifth of patients.4 Strong linkage studies associating SCN5A with BrS do not exist, with the 
exception of families with overlap phenotypes with LQTS and PCCD.41 Additionally, the 
genotype-phenotype correlation within families shows worrying mismatch. Probst et al, 
described 5 out of 13 large BrS families with known SCN5A mutations with several individuals 
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with a type 1 Brugada ECG pattern within the same family who were mutation-negative.42 
Mutations in 22 other genes encoding components and interacting proteins of the sodium 
channel, calcium channel, and potassium channels have also been implicated in BrS (Table 2) 
however few are based on strong linkage studies and most are rare.4, 43  
Furthermore, a genome-wide association study identified three SNPs with additive effects 
on the likelihood of BrS irrespective of the presence of an SCN5A mutation.44 These included 
two SNPs at the SCN5A and SCN10A locus; SCN10A encoding the alpha subunit of the neuronal 
Nav1.8 current associated with nociception. This prompted investigation by Hu et al that 
suggested that mutations in SCN10A are present in up to 16% of BrS patients.45  A 
contemporaneous study assessed the burden of rare coding variants in BrS associated genes in 
patients compared to a control group and only showed enrichment of SCN5A. This concluded 
that previously reported genes including SCN10A do not account for BrS cases in patients of 
European ancestry.46 Additionally, a subsequent study of 45 known cardiac genes in SCN5A 
negative cases showed enrichment of the DSC2 gene linked to arrhythmogenic right ventricular 
cardiomyopathy (ARVC) but not the other BrS genes.47 These data reinforced the possible role 
for ARVC associated rare variants in BrS that had already been proposed for the PKP2 gene in 
an earlier study.48 Another study of potential novel candidate genes in SCN5A negative cases 
showed a similar low yield although a probable mutation was identified in TBX5, a transcription 
factor for SCN5A and SCN10A.49 The study also confirmed previous findings that SNPs at the 
SCN10A locus associates with BrS but rare variation was not significantly associated. 
Collectively these studies support the theory that BrS is an oligogenic disease with the potential 
that ion channel and structural rare variants may have modulatory influences upon a ‘common 
substrate’. Together with other factors such as age, gender and environmental exposures, these 
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affect the susceptibility for the BrS phenotype and potentially contribute to the subtle structural 
disease that has been associated with the disorder. This may also account for the unexpectedly 
high yield of ajmaline provocation in the general population, whereby susceptibility to BrS is 
partly due to genetic variation prevalent in the general population.31 The role for diagnostic 
genetic testing is therefore relatively limited at this time until we are able to dissect the 
interaction of rare and common variation. 
Catecholaminergic Polymorphic Ventricular Tachycardia 
CPVT is a highly lethal, rare inherited arrhythmia syndrome characterised by bidirectional and 
polymorphic VT which is adrenergically stimulated, typically through physical exertion.50, 51 The 
diagnostic criteria require a structurally normal heart and normal baseline ECG, with the 
development of polymorphic or bidirectional VT following exercise or catecholamine, usually in 
a patient aged <40yrs.1 CPVT can also be diagnosed in patients who are found to be carriers of a 
known clearly pathogenic genetic variant as well as in family members of an index case who 
develop premature ventricular contractions (PVCs) during exercise.1 
The pathophysiology of CPVT is dependent upon abnormal intracellular calcium 
handling leading to triggered activity.52 Linkage studies in 2 large Finnish families with 
autosomal dominantly inherited CPVT first identified linkage at chromosome 1q42-43.53 
Subsequent studies indicated the gene encoding the cardiac ryanodine receptor gene (RYR2) to 
be responsible (CPVT1).1, 4 In CPVT, RYR2 is ’leaky’ under adrenergic activation, causing an 
excess of calcium release into the cytosol in diastole resulting in increased activation of the 
sodium-calcium exchanger and delayed after-depolarisations.54 A rarer form of autosomal 
recessive CPVT (CPVT2) is known to result from mutations in the cardiac calsequestrin gene 
(CASQ2) an important calcium storage and buffering protein in the sarcoplasmic reticulum 
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interacting with RYR2.4  A recent study has also shown linkage to a heterozygous CASQ2 variant 
in autosomal dominant CPVT for the first time.55 
Collectively, these two genes combined account for around 50-65% of cases of CPVT.12 
Other genes, including Calmodulin (CALM1), Triadin (TRDN), TECLR, Ankyrin-B (Ank2) and 
KCNJ2 account for rare cases of CPVT.4, 56 Whether Ank2 and KCNJ2 represent phenocopies or 
overlap syndromes with LQT4 and 7 respectively remains a moot point (Table 3). 
Short QT Syndrome 
SQTS is a rare inherited arrhythmia syndrome characterised by syncope or sudden cardiac death 
associated with a shortened QTc interval. The diagnosis requires the presence of a very short 
QTc ≤330ms, or  a QTc ≤360ms in association with one of the following: family history of 
SQTS, pathogenic mutation, family history of sudden death at age ≤40 years; and/or survival of a 
VT/VF episode in the absence of  heart disease.1 SQTS was first described in 200057 and since 
then candidate gene studies have linked SQTS to missense mutations causing gain of function in 
potassium channels (KCNH2- SQT1, KCNQ1- SQT2, KCNJ2- SQT3).4, 58 There is also an 
association with loss of function mutations in calcium channels (CACNA1C and CACNB2b) in 
association with a BrS phenotype.4, 58 SQTS is very rare with the largest series of 73 patients 
demonstrating a low genetic yield of 14% despite familial disease being evident in 44%.58 It is 
unclear whether there may be an overlap with idiopathic VF (IVF) cases with only moderate QT 
shortening leading to underdiagnosis. 
Idiopathic Ventricular Fibrillation 
IVF describes patients who experience a resuscitated cardiac arrest, ideally with documented VF 
in the absence of other causes for VF i.e. metabolic, toxicological, cardiac (including other 
channelopathies and structural heart disease), respiratory and infectious.1 The arrhythmias are 
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believed to be precipitated by short-coupled premature ventricular contractions (PVCs) due to 
Purkinje fibre potentials leading to polymorphic VT.59-61  
Whilst IVF remains largely unexplained, the genetic basis for disease has been proposed 
in some cases. Alders et al linked disease with DPP6 gene though a genome-wide haplotype 
sharing analysis in three distantly related Dutch families. Carriers demonstrated high penetrance 
with 50% experiencing an episode of VF or sudden death before age 58.62 Marsman et al used 
exome sequencing to link IVF to CALM1 in a family of Moroccan descent.63 A recent report 
described a family with a likely IVF phenotype, with short-coupled PVCs at rest and a novel 
RYR2 mutation H29D causing diastolic calcium leak at rest.64 Finally a very recent report 
highlights IRX3 as a putative gene in humans and animal models.65 Collectively these reports 
suggest potential monogenic causes for IVF. However due to the lack of large IVF families it 
remains possible that the disease may be oligogenic.66 Additionally, the prevalence of IVF is 
declining as more patients initially diagnosed with IVF are subsequently diagnosed with a 
different inherited arrhythmia syndrome such as BrS.66 
Progressive Cardiac Conduction System Disease (PCCD) 
Progressive cardiac conduction system disease (PCCD) is diagnosed in young patients (<50 
years) exhibiting abnormalities of conduction with and without a structurally normal heart in the 
absence of skeletal myopathies.1 When there is a clear familial pattern to disease it is typically 
autosomal dominant and genetic testing has diagnostic utility.1 The majority of familial cases 
with a structurally normal heart are attributed to mutations in SCN5A and TRPM4.12 Cases due to 
SCN5A mutations can be associated with a BrS overlap syndrome.12, 41, 67 There are also rare 
associations with other genes (SCN1B, SCN10A, KCNK17).68 PCCD with congenital heart 
disease is associated with transcription factor mutations (e.g. NKX2.5, GATA4)69 and PCCD 
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with dilated cardiomyopathy or LV dysfunction is associated with lamin A/C (LMNA) or desmin 
(DES) variants.12 The presence of a LMNA mutation carries prognostic utility and may influence 
ICD implantation.1   
Genetic Testing and Next Generation Sequencing  
Identification of the likely pathogenic variant in a family permits predictive (cascade) testing in 
family members. Those who are not found to carry the variant are released from regular clinical 
screening.70 The best approach to improving the pre-test probability of a pathogenic variant 
being identified is to ensure the clinical phenotype is clearly defined, whether there is a family 
history of disease and that only genes which are plausible for the phenotype are assessed.12 
Diagnostic testing had traditionally relied upon Sanger sequencing and disease causation 
or pathogenicity was often inferred only by absence of a variant in relatively small control 
populations.  Since 2005, next-generation sequencing (NGS) methods have become increasingly 
available including cardiac gene panel testing, whole exome and whole genome sequencing. 
These allow large volumes of data to be analysed quickly and comprehensively at lower cost and 
have helped identify causative genes in disease where traditional methods have previously 
failed.71 These differing approaches as well as their relevant advantages and disadvantages are 
shown in Supple entary Material.  
NGS has also facilitated large public databases of genetic variation such as the 1000 
Genomes project, the Exome Sequencing Project (ESP) or Exome Aggregation Consortium 
(ExAC) that have indicated rare variants to be more common than expected.30 For example, in 
SCN5A there is a 3-5% background ‘noise’ of rare variants amongst healthy individuals.72 
Therefore up to 1 in 20 so-called positive genetic tests for BrS could in fact be false-positives.30 
The current ‘signal-to-noise ratio’ for the top four inherited arrhythmia genes ranges between 
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4.5:1 (SCN5A for LQT3) and 70:1 (KCNQ1 for LQT1).73 Additionally, variants previously 
thought of as being pathogenic in early Sanger studies are now accepted to be too common to be 
causative of rare disease and are therefore false positives. For example, 1 in 23 individuals in the 
ESP database carried a previously published BrS-associated variant.74 Similarly Refsgaard et al 
identified 33 rare variants previously associated with LQTS in the ESP database suggesting a 
disease prevalence of 1 in 31 rather than 1 in 2000.75 Ghouse et al showed that 10 variants 
previously associated with LQTS were in fact found frequently amongst a Danish population 
sample.76 Finally, Van Driest et al showed no significant difference in arrhythmic phenotype 
between those with and without rare KCNH2 or SCN5A variants in an unselected population. 77 
They also showed poor concordance amongst laboratories when designating rare variants as 
pathogenic.  
Thus in order to strengthen utility of contemporary genetic testing there are stringent 
criteria to determine pathogenicity.  It is no longer considered a binary variable, but instead a 
probabilistic spectrum of pathogenicity as shown in Figure 1.70, 78, 79 Criteria have been 
published by the American College of Medical Genetics and Genomics (ACMG) and are 
currently being updated with cardiac specific recommendations.80  
Assessing Pathogenicity 
Online databases of previously reported pathogenic variants have provided important tools for 
recognising unequivocally pathogenic variants although they are only as robust as the data 
entered and require regular updating and stringent curation. The ClinVar 
(www.ncbi.nlm.nih.gov/clinvar/) and ClinGen (www.clinicalgenome.org) initiatives offer 
important opportunities for global harmonisation of such data.81 
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Rarity can still be helpful when assessing likelihood of pathogenicity.82 The public 
databases are integral to determining which variants are truly rare or novel and which are part of 
normal background genetic variation within cardiac inherited arrhythmia genes.30 The prevalence 
of the disease being tested for should, however, be considered. For example, the disease 
prevalence of CPVT is 1/10,000; therefore, a variant with a population frequency of 0.0001, 
whilst rare, would potentially account for all CPVT cases globally and is therefore too common 
to be pathogenic. Novelty or substantially lower allele frequency than the disease revalence is 
therefore required to support pathogenicity. 
Loss of function is a known mechanism of disease pathogenesis for most inherited 
arrhythmia syndromes and an important step in assessing pathogenicity is reviewing the 
predicted effect of the variant on protein function. This is relatively straightforward for nonsense, 
frameshift or splice-site mutations but less so for missense variants. In silico software tools and 
functional studies, either in vivo or in vitro, can then also be used to assess the physiological 
effect of the variant and predict likelihood of pathogenicity although they are not always 
reliable.30, 80, 82 Kapplinger et al used multiple in silico tools and ion channel topography to 
improve variant classification as benign or pathogenic.72 All tools bar the Grantham score 
showed some predictive value although none showed strong independent utility. 
Despite these efforts variants of uncertain significance (VUS) have become increasingly 
problematic. These are typically absent from population databases and may have computational 
evidence suggestive of pathogenicity. Lack of functional or segregation data however means that 
the variant cannot be classified as likely pathogenic or benign. Genetic counselling is critical to 
ensure the patients understand this potential complication of genetic testing.12 Predictive testing 
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should therefore only be performed in monogenic disease when a variant has been classified as 
pathogenic or likely pathogenic.70  
The Changing Landscape of Inherited Arrhythmia Syndromes  
Inherited arrhythmia syndromes have typically been attributed to autosomal dominant 
inheritance due to monogenic abnormalities. As discussed above, these diseases may be 
genetically more complex and oligogenic, particularly in BrS (Figure 2A). The simple genotype 
equals phenotype equation is also increasingly questioned.  This was first evidenced by SCN5A 
overlap syndrome of BrS, PCCD and LQTS41 followed by association with other phenotypes,67 
as well as dilated cardiomyopathy and atrial fibrillation.4 There is also vidence of CPVT and 
LQTS overlap phenotypes due to different ANK2 and KCNJ2 mutations. The evolving 
relationship between genotype and phenotype is depicted in Figure 2B. 
New Entities  
Calmodulinopathies 
Calmodulin is a ubiquitous calcium binding protein.83 The importance of calmodulin binding to 
KCNQ1 for correct IKs channel function was first highlighted using patch-clamp experiments 10 
years ago.84 Shamgar et al showed that LQTS mutations located near the C-terminal affect 
calmodulin binding, channel gating and assembly as well as calcium-sensitive IKs-current 
stimulation. Defective calcium binding due to mutant calmodulin causes ventricular action 
potentials to be significantly prolonged.85, 86 This cellular work has translated to the bedside with 
the evolution of the “calmodulinopathies”. 
Human calmodulin is encoded by three separate genes (CALM1, CALM2, CALM3), 
located on three different chromosomes, with the same amino acid sequences present in the three 
protein products of the genes.87 Mutations in CALM1 and CALM2 were first identified through 
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whole exome sequencing in two unrelated infants with severe QT prolongation and recurrent 
cardiac arrest in infancy.10 This was confirmed in two additional similar cases.10 A large linkage 
study in a Swedish family with a dominantly inherited CPVT-like phenotype established linkage 
to a heterozygous CALM1 mutation.11 A second CPVT patient was identified with a different de 
novo missense mutation in CALM1.11 A recent exome sequencing study assessed the prevalence 
of CALM1-3 variants in 38 gene-negative LQT patients and found a significant proportion of 
calmodulin variants in this cohort compared to ExAC (13.2% vs 0.04%).9 These cases had a 
young age of onset, high rate of cardiac arrest and severe QTc interval prolongation. Functional 
characterisation of one calmodulin variant (E141G) revealed a reduction in calcium binding 
affinity by a factor of 11 and functionally dominant loss of inactivation of L-type calcium 
channels with mild effects on late sodium current. CALM1 has also been linked to familial 
idiopathic VF.63 Currently CALM1 and CALM2 are known as LQT14 and LQT15 genes (Table 
1) whilst CALM1 is also CPVT4 gene (Table 3). CALM3 has not yet been classified. It seems the 
term “calmodulinopathies” encompasses an LQTS/CVPT/IVF overlap syndrome with severe 
arrhythmic phenotype demonstrated from a young age (Figure 2B). 
Triadin Knockout Syndrome 
Triadin (TRDN) is an important protein in the formation of the macromolecular calcium release 
complex, working with junctin to anchor CASQ2 to RYR2.88 Mouse models with complete 
knockout of the TRDN gene have significantly altered structure and function of the calcium 
release complex.89 The first study of TRDN was performed in a cohort of 97 patients with 
genotype negative CPVT and identified three mutations in two families with recessive CPVT.88 
Two mutations were premature truncations whilst the third was a missense mutation with 
subsequent functional studies confirming mutant TRDN protein. More recently triadin knockout 
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syndrome has also been associated with a distinct autosomal recessive LQTS phenotype.8 Exome 
sequencing in a trio of unaffected parents with a severely affected 10-year-old daughter 
identified a homozygous frameshift mutation. Subsequent sequencing in a cohort of 33 
additional unaffected patients with gene negative LQTS revealed 4 additional patients with 
homozygous or compound heterozygous TRDN frameshift mutations. All patients carried the 
same distinct phenotype of extensive T-wave inversion in the precordial ECG leads V1-V4 
(similar to ARVC), QTc prolongation and severe disease expression at a young age, with 
arrhythmias particularly precipitated by exercise.8 The mechanism underpinning the TRDN 
knockout syndrome appears to be reduction in negative feedback on th  L-type calcium channel 
leading to increased intracellular calcium, increased frequency of sarcoplasmic reticulum 
calcium release and subsequent VT, particularly with adrenergic stimulation.89 L-type calcium 
channel blocking agents have been proposed as potential therapeutic options in patients with this 
distinct syndrome.8 The triadin knockout syndrome appears to be an overlap syndrome with a 
LQTS/CPVT/ARVC overlap phenotype (Figure 2B). 
Gene Therapies for Inherited Arrhythmia Syndromes 
Recent work has highlighted that it may be possible to cure arrhythmia syndromes in the not too 
distant future. A CASQ2 knockout mouse model of CPVT was rescued with CASQ2 via an 
adeno-associated viral vector (AAV9). The arrhythmic phenotype and ultrastructural 
abnormalities were also rescued with absence of arrhythmias in the rescued mice.90 Subsequent 
work showed similar success in rescuing the phenotype from a knock-in murine model with 
CASQ2 R33Q homozygous mutation with administration of AAV9-CASQ2 at birth. The mice 
continued to display no evidence of CPVT at 1 year of age. Whilst still early in evolution, these 
animal models provide an exciting insight into where potential gene therapy options may arise. 
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Conclusion  
Our understanding of inherited arrhythmia syndromes continues to evolve. Clinicians must 
continue to use caution when interpreting genetic variants and when using genetic results to 
determine management of patients and families with inherited arrhythmia syndromes. There is 
increasing genetic and phenotypic heterogeneity and mounting evidence that BrS is an 
oligogenic disorder. The era of NGS has evolved rapidly providing challenges including 
attributing pathogenicity, background genetic noise and increased detection of VUS; as well as 
new opportunities, including identification of new inherited arrhythmia entities such as the 
calmodulinopathies and Triadin disease. Our early understanding that a particular genotype 
causes a specific phenotype is further challenged with these new entities.  
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Table 1: Genes associated with long QT syndrome (modified from Wilde and Behr)4, 8-11  
 
LQTS type Gene Protein Current Frequency
LQT1 KCNQ1 Kv7.1 IKs 40-45% 
LQT2 KCNH2 KV11.1 IKr 30-35% 
LQT3 SCN5A Nav1.5 INa 10% 
LQT4 ANK2 Ankyrin-B Na+/K+ 1% 
LQT5 KCNE1 MinK IKs 1% 
LQT6 KCNE2 MiRP1 IKr Rare 
LQT7 KCNJ2 Kir2.1 IK1 Rare 
LQT8 CACNA1C CaV1.2 ICa-L Rare 
LQT9 CAV3 Caveolin3 INa Rare 
LQT10 SCN4B SCNβ4subunit INa Rare 
LQT11 AKAP9 Yotiao IKs Rare 
LQT12 SNTA1 Syntrophin-α1 INa Rare 
LQT13 KCNJ5 Kir3.4 IKACH Rare 
LQT14 CALM1 Calmodulin1 Calcium signalling Rare 
LQT15 CALM2 Calmodulin2 Calcium signalling Rare 
LQT16 TRDN Triadin ICa-L Rare 
Jervell and Lange-Nielsen syndrome (Autosomal Recessive)  
JLN1 KCNQ1 Kv7.1 IKs Rare 
JLN2 KCNE1 MinK IKs Rare 
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Table 2: Genes Associated with Brugada Syndrome (Modified from Wilde and Behr; and 
Gourraud et al.)4, 43 
 
Name Gene Protein Prevalence
BrS1 SCN5A α-subunit Nav1.5 Sodium channel 20-25% 
BrS2 GPD1L Glycerol-3-phosphate dehydrogenase 1-like rare 
BrS3 CACNA1C α-subunit α1C Cav1.2 Calcium channel 1-2% 
BrS4 CACNB2b β-subunit Cavβ2b calcium channel 1-2% 
BrS5 SCN1b β-subunit Navβ1 sodium channel rare 
BrS6 KCNE3 β-subunit MiRP2 potassium channel rare 
BrS7 SCN3b β-subunit Navβ3 sodium channel rare 
BrS8 HCN4 Hyperpolarization-activated cyclic nucleotide-gated channel 4 rare 
BrS9 KCND3 α-subunit KV4.3 potassium channel rare 
BrS10 KCNJ8 α-subunit KIR6.1 potassium channel rare 
BrS11 CACNA2D1 δ-subunit Cavα2δ1 calcium channel rare 
BrS12 KCNE5 β-subunit potassium channel rare 
BrS13 RANGRF RAN guanine nucleotide release factor rare 
BrS14 KCND2 α-subunit KV4.2 potassium channel rare 
BrS15 TRPM4 Calcium-activated non-selective ion channel rare 
BrS16 SCN2B β-subunit Navβ2 sodium channel rare 
BrS17 PKP2 Plakophilin 2 rare 
BrS18 ABCC9 ATP-sensitive potassium channels rare 
BrS19 SLMAP Sarcolemma-associated protein rare 
BrS20 KCNH2 α-subunit of HERG potassium channel rare 
BrS21 SCN10A α-subunit Nav1.8 sodium channel 1-16% 
BrS22 FGF12 Fibroblast growth factor 12 rare 
BrS23 SEMA3A Semaphorin family protein rare 
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Table 3: Genes associated with CPVT (Modified from Wilde and Behr)4 
 
 
Name 
 
Gene Protein Frequency 
 
CPVT1 
 
RYR2 Cardiac Ryanodine Receptor 2 50-60% 
 
CPVT2 
 
CASQ2 Cardiac Calsequestrin  ~5% 
CPVT3 TECLR 
 
Originally mapped to chromosome 7 p14-p22, 
now reallocated to chromosome 4 
 
Rare 
 
CPVT4 
 
CALM1 Calmodulin Rare 
 
CPVT5 
 
TRDN Triadin Rare 
 
? LQT4 overlap 
 
ANK2 Ankyrin B Rare 
 
? LQT7 overlap 
 
KCNJ2 Potassium Inwardly Rectifying Channel Kir2.1 Rare 
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Figure Legends: 
 
Figure 1: Probabilistic nature of genetic results (Modified with permission from Maron et al)78 
 
Figure 2: (A) Spectrum of underlying genetic abnormalities in inherited arrhythmia syndromes 
(B) Changing landscape of genotype-phenotype interaction in inherited arrhythmia syndromes   
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